Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PYRIDINES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed2003

Ruthenium complexes of 2-[(4-(arylamino)phenyl)azo]pyridine formed via regioselective phenyl ring amination of coordinated 2-(phenylazo)pyridine: isolation of products, X-ray structure, and redox and optical properties.

Aromatic ring amination reactions in the ruthenium complex of 2-(phenylazo)pyridine is described. The substitutionally inert cationic brown complex [Ru(pap)(3)](ClO(4))(2) (1) (pap = 2-(phenylazo)pyridine) reacts smoothly with aromatic amines neat and in the presence of air to produce cationic and intense blue complexes [Ru(HL(2))(3)](ClO(4))(2) (2) (HL(2) = 2-[(4-(arylamino)phenyl)azo]pyridine). These were purified on a preparative TLC plate. The X-ray structure of the new and representative complex 2c has been solved to characterize them. The results are compared with those of the starting complex, [Ru(pap)(3)](ClO(4))(2) (1). The transformation 1 --> 2 involves aromatic ring amination at the para carbon (with respect to the diazo function) of the pendant phenyl rings of all three coordinated pap ligands in 1. The transformation is stereoretentive, and the amination reaction is regioselective. The extended ligand HL(2) coordinates as a bidentate ligand and chelates to ruthenium(II) through the pyridine and one of the azo nitrogens. The amine nitrogen of this bears a hydrogen atom and remains uncoordinated. Similarly, the amination reaction on the mixed-ligand complex [Ru(pap)(bpy)(2)](ClO(4))(2) produces the blue complex [Ru(HL(2))(bpy)(2)](ClO(4))(2) (3) as anticipated. The reactions of [RuCl(2)(dmso)(4)] and [Ru(S)(2)(L)(2)](2+) (dmso = dimethyl sulfoxide, S = labile coordinated solvent, L = 2,2'-bipyridine (bpy) and pap) with the preformed HL(2) ligand have been explored. The structure of the representative complex [RuCl(2)(HL(2a))(2)] (5a) is reported. It has the chlorides in trans configuration while the pyridine as well as azo nitrogens are in cis geometry. Optical spectra and redox properties of the newly synthesized complexes are reported. All the ruthenium complexes of HL(2) are characterized by their intense blue solution colors. The lowest energy transitions in these complexes appear near 600 nm, which have been attributed to intraligand charge-transfer transitions. For example, the lowest energy visible range transition in [Ru(HL(2b))(3)](2+) appears at 602 nm and its intensity is 65 510 M(-1) cm(-1). All the tris chelates show multiple-step electron-transfer processes. In [Ru(HL(2))(3)](2+), six reductions waves constitute the complete electron-transfer series. The electrons are believed to be added successively to the three azo functions. In the mixed-ligand chelates [Ru(HL(2))(pap)(2)](2+) and [Ru(HL(2))(bpy)(2)](2+) the reductions due to HL(2), pap, and bpy are observed.

Journal Article↗
PubMed2005

Structure and reactivity of trans-bis[2-(2-chloroethyl)pyridine]palladium chloride (1). A study on the elimination reaction of 1 and 2-(2-chloroethyl)pyridine induced by quinuclidine in acetonitrile.

[reaction: see text] The trans-bis[2-(2-chloroethyl)pyridine]palladium chloride (1) has been prepared and structurally characterized by X-ray spectroscopy and computational study. The X-ray structure of 1 is consistent with the trans isomer (with respect to Pd). The NMR spectrum and the computational study are in agreement with an equilibrium in CD3CN solution between two isomers of the trans structure. The reaction of the palladium complex with quinuclidine in CH3CN, at 25 degrees C, leads to competing elimination and displacement reactions with formation of vinylpyridine and chloroethylpyridine in a ratio of 1.5:1. However, the rate constant for formation of uncoordinated (vinyl)pyridine monitored by HPLC (kQ(HPLC) = 2.3 x 10(-3) M(-1) s(-1)) is nearly 3 times slower than a rate constant monitored spectrophotometrically (kQ = 6.5 x 10(-3) M(-1) s(-1)). This suggests that the initial product of elimination is a palladium complex of vinylpyridine and that displacement from this complex is partially rate determining in the formation of the uncoordinated product. A study by UV spectroscopy at lambda = 295 nm of trans-bis[2-(2-chloroethyl)pyridine-d2]palladium chloride with quinuclidine (Q) has shown the presence of a significant primary kinetic isotope effect, kQ(H)/kQ(D) = 1.8, for the elimination reaction within the Pd complex, 1. The second-order rate constant for the beta-elimination reaction from 2-(2-chloroethyl)pyridine induced by quinuclidine in CH3CN at 25 degrees C is kQ(FREE) = 6.2 x 10(-6) M(-1) s(-1). It can be observed as a significant activation (about 3 orders of magnitude) of the beta-elimination reaction within the complex 1 with respect to the free 2-(2-chloroethyl)pyridine. The possible mechanism in agreement with these results is discussed.

Journal Article↗
PubMed2003

In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine).

In vivo receptor occupancy of mGlu5 receptor antagonists was quantified in rat and mouse brain using the mGlu5 receptor selective antagonist [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine) ([3H]methoxy-PEPy). Administration of [3H]methoxy-PEPy (50 microCi/kg i.v.) to mGlu5 receptor-deficient mice revealed binding at background levels in forebrain, whereas wild-type mice exhibited 14-fold higher binding in forebrain relative to cerebellum. Systemic administration of the mGlu5 receptor antagonists 2-methyl-6-(phenylethynyl)pyridine (MPEP) and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) reduced the binding of [3H]methoxy-PEPy in rats and mice, reflecting mGlu5 receptor occupancy by these compounds. MPEP (10 mg/kg i.p.) and MTEP (3 mg/kg i.p.) maintained >75% receptor occupancy for 2 h in rats, while in mice MPEP and MTEP achieved >75% occupancy for only 30 and 15 min, respectively. Compound levels in plasma were substantially lower in mice suggesting species differences in receptor occupancy result from differences in absorption or metabolism of the compounds. These findings demonstrate that [3H]methoxy-PEPy is useful for determining the occupancy of mGlu5 receptors in the brain.

Animals↗
PubMed1994

Novel cAMP PDE III inhibitors: imidazo[4,5-b]pyridin-2(3H)-ones and thiazolo[4,5-b]pyridin-2(3H)-ones and their analogs.

The transformation of milrinone to 1,3-dihydro-5-methyl-6-(4-pyridinyl)-2H-imidazo[4,5-b]pyridin-2-one (13a), 5-methyl-6-(4-pyridinyl)thiazolo[4,5-b]pyridin-2(3H)-one (51), and 7-methyl-6-(4-pyridinyl)-1,8-naphthyridin-2(1H)-one (22) resulted in very potent cAMP PDE III inhibitors with in vitro activity in the nanomolar range. 1,3-Dihydro-2H-imidazo[4,5-b]pyridin-2-ones 13 were prepared from 2-aminopyridine-3-carboxylic acids (7, 10) via Curtius rearrangement. 1,8-Naphthyridin-2(1H)-one 22 and the corresponding 3,4-dihydro derivative 28 were prepared from 5-bromo-2-methyl[3,4'-bipyridin]-6-amine (21) and 5-bromo-2-methyl[3,4-bipyridin]-6(1H)-one (24), respectively, via Heck reaction. Thiazolo[4,5-b]pyridin-2(3H)-ones 35 were prepared from 6-bromo[3,4'-bipyridin]-6-amines 30 and 32 via a four-step sequence. Treatment of 6-amino-2-methyl[3,4'-bipyridine]-5-thiol (59) with ethyl bromoacetate and ethyl bromodifluoroacetate gave pyridothiazinones 60 and 61, respectively.

3',5'-Cyclic-AMP Phosphodiesterases↗
PubMed1990

Potent anticonflict activity and lessening of memory impairment with a series of novel [1]benzothieno[2,3-c]pyridines and 1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridines.

[1]Benzothieno[2,3-c]pyridines (10a-c, 11, 12a-t, and 13a,b) and 1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridines (3a-c, 7, 8a-c, and 9) were synthesized. The compounds are bioisosteres of beta-carbolines and 1,2,3,4-tetrahydro-beta-carbolines where the indole nitrogen is replaced by sulfur. Their pharmacological activity was evaluated in a water lick conflict test in rats and a passive avoidance test in mice. In the 1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine series, the presence of ethyl ester (3b) or cyclohexyl carboxamide (7) groups at C-3 conferred good anticonflict activity and lessening of memory impairment, while N-acylation of 3b abolished activity. In the [1]benzothieno(2,3-c]pyridine series, the aminoethyl carboxamide (12a) group at C-3 also conferred activity, but other amides studied were not active. The most potent compounds (3b, 7, and 12a) were also administered orally and had potent anticonflict and antiscopolamine amnesia-reversal activity. These compounds did not bind to the BZP receptor in spite of having structures similar to those of beta-carbolines. Compound 7 bound strongly to 5-HT1A receptors and would be expected to be a novel anxiolytic.

Animals↗
PubMed1978

Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.

In a study of nonsteroidal antiinflammatory and analgesic agents, a series of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones-and 3-(substituted phenyl)triazolo[4,5-b]pyridines was prepared. Many of the imidazolones were alkylated on the free nitrogen. In a modified Randall-Selitto analgesic assay, the pain thresholds of both the inflamed and normal foot were elevated. This is not commonly observed with nonsteroidal antiinflammatory agents. The most active compounds were 1,3-dihydro-3[3,4-(methylenedioxy)phenyl]imidazo[4,5-b]pyridin-2-one (I-15) and its N-allyl (I-21) and N-isopropyl (I-121) derivatives. In the triazole series the 3-(2-fluoro- and 2,4-difluorophenyl)triazolo[4,5-b]pyridines (T-1 and T-8) were the best. The imidazole compounds were somewhat superior in analgesic activity to codeine and d-propoxyphene without showing any narcotic characteristics. Some of the compounds also possessed activity against carrageenan-induced foot edema in the rat, so these compounds represent a new class of nonnarcotic analgesic antiinflammatories, capable of producing a greater degree of analgesia than that obtainable with other nonsteroidal antiinflammatory agents.

Animals↗
PubMed2004

Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents.

2-[5-(4-Amidinophenyl)-furan-2-yl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine-6-carboxamidine acetate salt (7) was synthesized from 2-[5-(4-cyanophenyl)-furan-2-yl]-imidazo[1,2-a]pyridine-6-carbonitrile (4a), through the bis-O-acetoxyamidoxime followed by hydrogenation in glacial acetic acid. Compound 4a was obtained in four steps starting with two successive brominations of 2-acetylfuran first with N-bromosuccinimide, and second with bromine to form alpha-bromo-2-acetyl-5-bromofuran (2) in a moderate yield. The product (3a), of the condensation reaction between 6-amino-nicotinonitrile and 2, undergoes Suzuki coupling with 4-cyanophenylboronic acid to furnish 4a in good yield. Acetate salt of 2-[5-(4-amidinophenyl)-furan-2-yl]-imidazo[1,2-a]pyridine-6-carboxamidine (8a) was obtained from 4a, through the bis-O-acetoxyamidoxime followed by hydrogenation in a mixture of ethanol/ethyl acetate. N-Methoxy-2-(5-[4-(N-methoxyamidino)-phenyl]-furan-2-yl)-imidazo[1,2-a]pyridine-6-carboxamidine (6) was prepared via methylation of the respective diamidoxime 5a with dimethyl sulfate. By these approaches eight new diamidines and four potential prodrugs were prepared. All of the diamidines showed strong DNA affinities as judged by high DeltaT(m) values. Six of the eight diamidines gave in vitro IC(50) values of 63 nM or less vs T. b. rhodesiense with two exhibiting values of 6 nM and 1 nM. Also, six of the eight diamidines gave in vitro IC(50) values of 88 nM or less vs P. falciparum with two exhibiting values of 14 nM. Excellent in vivo activity in the trypanosomal STIB900 mouse model was found for five of the diamidines on ip dosage; these compounds gave 4/4 cures in this model. The oral activity of the prodrugs was modest with only one showing 2/4 cures in the same mouse model.

Animals↗
PubMed2002

[3-nitrobenzylidene-2,3(3H,5H)-furandione in the Hantzsch pyridine synthesis. 1. A new approach to furo(3,4-b)pyridines].

The nitrobenzylidenefurandiones 7 react with acetoacetic ester (8) and ammonium acetate or 3-aminocrotonic esters (9a, b) and 2-amino-pent-2-en-4-on (9c), respectively heating in acetic acid to yield the tetrahydrofuro[3,4-b]pyridines 10. The dehydrogenation of 10 using nitric acid or activated manganese dioxide leads to the dihydrofuro[3,4-b]pyridines 12. When the reaction is carried out with the tetronic acid derivatives 7 and the enaminocarbonyl compounds 9 at 30 degrees C in tert-butanol the hexahydro-7a-hydroxyfuro[3,4-b]pyridines 11 are obtained. Treating the N,O-acetales 11 with acetic anhydride in pyridine affords the annulated lactones 10.

Furans↗
PubMed1999

Stereochemically Controlled Synthesis of Ruthenium(II) Complexes Containing Bis(oxazolin-2'-yl)pyridine Ligands. X-ray Crystal Structures of trans-[RuCl(2)(PPh(3)){kappa(3)-N,N,N-(S,S)-(i)Pr-pybox}] and [RuCl(=C=C=CPh(2))(PPh(3)){kappa(3)-N,N,N-(S,S)-(i)Pr-pybox}][PF(6)] ((S,S)-(i)Pr-pybox= 2,6-Bis[4'-(S)-isopropyloxazolin-2'-yl]pyridine).

The treatment of achiral and chiral bis(oxazolin-2'-yl)pyridine (pybox) complexes trans-[RuCl(2)(eta(2)-H(2)C=CH(2))(k(3)-N,N,N-pybox)] [pybox= 2,6-bis(dihydrooxazolin-2'-yl)pyridine] (1a) and [RuCl(2)(eta(2)-H(2)C=CH(2))(k(3)-N,N,N-(SS)-(i)Pr-pybox}] [(SS)-(i)Pr-pybox= 2,6-bis[4'-(S)-isopropyloxazolin-2'-yl]pyridine] (1b) with an excess of triphenylphosphine in dichloromethane at 50 degrees C leads to the formation of the first ruthenium(II) derivatives containing both bis(oxazolin-2'-yl)pyridine and phosphine ligands trans-[RuCl(2)(PPh(3))(kappa(3)-N,N,N-pybox)] (2a) and trans-[RuCl(2)(PPh(3)){kappa(3)-N,N,N-(SS)-(i)Pr-pybox}] (2b). Chiral complex 2b slowly isomerizes in acetone at 50 degrees C to generate cis-[RuCl(2)(PPh(3)){kappa(3)-N,N,N-(SS)-(i)Pr-pybox}] (3). Complex 3 can be also obtained from the reaction of 1b with PPh(3) in MeOH. The structure of 3 has been confirmed by X-ray crystallography [orthorhombic; space group P2(1)2(1)2(1); Z = 4; a = 12.772(6) Å, b = 15.208(5) Å, c = 19.601(7) Å; final R1= 0.0565 and wR2 = 0.0944 (both for I > 2sigma(I))]. The reaction of the achiral pybox complex 2a with 1,1-diphenyl-2-propyn-1-ol and AgBF(4) in CH(2)Cl(2) stereoselectively affords the cationic allenylidene derivative [RuCl(=C=C=CPh(2))(PPh(3))(kappa(3)-N,N,N-pybox)][BF(4)] (4a), while the methoxycarbene complex [RuCl{=C(OMe)CH=CPh(2)}(PPh(3))(kappa(3)-N,N,N-pybox)][PF(6)] (5) is obtained when the reaction is conducted in methanol and in the presence of NaPF(6), via the addition of MeOH to the initially formed allenylidene complex 4a. In contrast, the chiral pybox complex 2b reacts with 1,1-diphenyl-2-propyn-1-ol and NaPF(6) in MeOH to give the stable allenylidene complex [RuCl(=C=C=CPh(2))(PPh(3)){kappa(3)-N,N,N-(SS)-(i)Pr-pybox}][PF(6)] (4b). The X-ray crystal structure of 4b [orthorhombic; space group P2(1)2(1)2(1); Z = 4; a = 14.79(3) Å, b = 16.254(8) Å, c = 22.917(18) Å; final R1 = 0.0545 and wR2 = 0.1381 (both for I > 2sigma(I))] shows an octahedral coordination of the ligands around the ruthenium atom with the chloride and triphenylphosphine ligands in a trans arrangement and mutually cis with respect to the allenylidene moiety. The allenylidene complex 4b is also formed by the reaction of the cis dichloride complex 3 with 1,1-diphenyl-2-propyn-1-ol and NaPF(6) in MeOH. IR, (1)H, (31)P{(1)H}, and (13)C{(1)H} NMR data of all novel compounds are also reported.

Journal Article↗
PubMed2004

catena-Poly[[(pyridin-4-ol-kappaN)silver(I)]-mu-pyridin-4-olato-kappa2N:O].

The title complex, [Ag(C(5)H(4)NO)(C(5)H(5)NO)](n), consists of a polymeric neutral chain involving both a neutral pyridin-4-ol ligand and a deprotonated pyridin-4-olate monoanion. The Ag(I) atom shows a T-shaped coordination geometry, defined by one N atom of the pyridin-4-ol and one O and one N atom of two independent pyridin-4-olate bridges; the N-Ag-N moiety is approximately linear. The polymeric chains are connected via strong O-H...O hydrogen bonds and offset pi-pi interactions into a three-dimensional network.

Journal Article↗
PubMed2005

Poly[[bis(pyridin-3-ol)manganese(II)]-di-mu-pyridin-3-olato].

In the title complex, [Mn(C5H4NO)2(C5H5NO)2]n or [Mn(mu-3-PyO)2(3-PyOH)2]n (3-PyO- is the pyridin-3-olate anion and 3-PyOH is pyridin-3-ol), the Mn(II) atom lies on an inversion centre and has octahedral geometry, defined by two N atoms and two deprotonated exocyclic O atoms of symmetry-related pyridin-3-olate ligands [Mn-N = 2.3559 (14) A and Mn-O = 2.1703 (11) A], as well as two N atoms of terminal 3-PyOH ligands [Mn-N = 2.3482 (13) A]. The Mn(II) atoms are bridged by the deprotonated pyridin-3-olate anion into a layer structure, generating sheets in the (-101) plane. These sheets are linked by O-H...O hydrogen bonds. There are also pi-pi and C-H...pi interactions in the crystal structure.

Journal Article↗
PubMed2002

Synthesis of pyridine nucleotide analogs consisting of nicotinoylamino acids by means of transglycosidation reactions catalyzed by mammalian pyridine nucleotide transglycosidases.

Besides isonicotinic acid analogs of pyridine nucleotides, 24 novel pyridine nucleotide cofactors that have an amino acid residue at the carbonyl carbon of the nicotinamide moiety have been prepared by means of transglycosidation reactions catalyzed by rabbit spleen and guinea pig spleen pyridine nucleotide transglycosidases. Their chemical properties were characterized by means of proton NMR, Fab-mass, and UV spectral measurement and phosphodiesterase digestion. Except for the isonicotinic acid ones, these nicotinoylamino acid analogs were shown to function as substrates for both the hydrolysis and the transglycosidation reactions catalyzed by the mammalian NAD glycohydrolases, though their substrate activities were lower than those with the original pyridine nucleotides (NMN, NAD, and NADP). They were inactive in regard to yeast alcohol dehydrogenase- and Thermoanaerobium brockii alcohol dehydrogenase (NADP dependent)-oxidation.

Animals↗
PubMed1991

Imidazo[4,5-b]pyridine derivatives of potential tuberculostatic activity, II: Synthesis and bioactivity of designed and some other 2-cyanomethylimidazo[4,5-b]pyridine derivatives.

Based on the analysis of Quantitative Structure--Activity Relationships (QSAR) three representatives of imidazo[4,5-b]pyridine derivatives of predicted high antibacterial activity against Mycobacterium tuberculosis were synthetized and tested bacteriologically. Excellent agreement of the predicted and experimentally observed bioactivity was noted. Additional new derivatives of 4-methyl-4H-2-cyanomethylimidazo[4,5-b]pyridine (7) and 2-(alpha-methylcyanomethyl)imidazo[4,5-b]pyridine (22) were also synthesized and some of them were tested for tuberculostatic activity. The compounds synthesized according to a standard "trial and error" approach appeared generally inactive.

Acetonitriles↗
PubMed2006

Bis(oxazoline) Lewis acid catalyzed aldol reactions of pyridine N-oxide aldehydes--synthesis of optically active 2-(1-hydroxyalkyl)pyridine derivatives: development, scope, and total synthesis of an indolizine alkaloid.

A new, short, and simplified procedure for the synthesis of optically active pyridine derivatives from pro-chiral pyridine-N-oxides is presented. The catalytic and asymmetric Mukaiyama aldol reaction between ketene silyl acetals and 1-oxypyridine-2-carbaldehyde derivatives catalyzed by chiral copper(II)-bis(oxazoline) complexes gave optically active 2-(hydroxyalkyl)- and 2-(anti-1,2-dihydroxyalkyl)pyridine derivatives in good yields and diastereoselectivities, and in excellent enantioselectivities-up to 99 % enantiomeric excess. As a synthetic application of the developed method, a full account for the asymmetric total synthesis of a nonnatural indolizine alkaloid is provided.

Acids↗
PubMed2004

2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.

Structure-activity relationship studies on 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 2 led to the discovery of 2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl)pyridine (10)-a highly potent and selective mGlu5 receptor antagonist with good brain penetration and in vivo receptor occupancy in rat and cross-species oral bioavailability.

Administration, Oral↗
PubMed1998

Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist.

Analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, (A-84543, 1) with 2-, 4-, 5-, and 6-substituents on the pyridine ring were synthesized. These analogs exhibited Ki values ranging from 0.15 to > 9,000 nM when tested in vitro for neuronal nicotinic acetylcholine receptor binding activity. Assessment of functional activity at subtypes of neuronal nicotinic acetylcholine receptors indicates that pyridine substitution can have a profound effect on efficacy at these subtypes, and several subtype-selective agonists and antagonists have been identified.

Cell Line↗
PubMed1989

The thieno[3,2-c]pyridine and furo[3,2-c]pyridine rings: new pharmacophores with potential antipsychotic activity.

Two new arylpiperazine derivatives, the 4-(1-piperazinyl)thieno- and -furo[3,2-c]pyridine ring systems, have been synthesized and appended via tetramethylene chains to various imide rings. Target compounds from each series were found to have significant activity in the blockade of apomorphine stereotypy and apomorphine-induced climbing, the Sidman avoidance response, and the conditioned avoidance response. In addition, while potent affinity for serotonin 5-HT1 and 5-HT2 receptors was observed for both the thieno- and furo[3,2-c]pyridine derivatives, the interaction of these molecules with the dopamine D2 receptor was weak. Electrophysiological studies of the lead prototypes from each series, involving compounds 22 and 33, indicate these two molecules have distinctively different effects on dopamine neurons in areas A9 and A10. Despite the similarity these molecules share in their behavioral indices of antipsychotic activity, it is likely that the thieno- and furo[3,2-c]pyridine rings employ different mechanisms to achieve this convergence of biological effects.

Amphetamines↗
PubMed1997

Antihypertensive effect of some oxazolo[3,2-a]pyridines, thiazolo[3,2-a]pyridines and pyrido[2,1-b]oxazines in conscious spontaneously hypertensive rats.

The antihypertensive activity of eighteen 'oxazolo[3,2-a]pyridine, thiazolo[3,2-a]pyridine and pyrido[2,1-b]oxazine derivatives has been evaluated in conscious spontaneously hypertensive rats (SHRs), and compared with that of nifedipine, used as reference. At a dose of 50 mg kg-1 (i.p.) eleven compounds resulted in a significant reduction in mean arterial blood pressure; four of the eleven were particularly effective, resulting in significant hypotension more than 6 h after administration and an effect that was still apparent after 24 h. The hypotension induced by nifedipine gradually decreased, disappearing 6-8 h after administration. The long-lasting activity shown by these compounds is, in general, not accompanied by reflex tachycardia. Intraperitoneal administration of two oxazolo[3,2-a]pyridine derivatives and two pyrido[2,1-b]oxazine derivatives resulted in potent and long-lasting antihypertensive action in SHRs. Further studies on the mechanism of action of these derivatives might help the determination of better structure-activity correlations and the design, synthesis and evaluation of better antihypertensive agents.

Animals↗